Scope note: this is formulation and solution science for research reagents. It contains no guidance on human use, dosing or administration.
The short answer
Bacteriostatic water (BW) is water with 0.9% benzyl alcohol. Its osmolality is about 83 mOsm/kg (my calculation from 9 g/L ÷ 108.14 g/mol, assuming ideality), so it is strongly hypotonic against the ~290 mOsm/kg of physiological fluids. A few mg/mL of a 4–5 kDa peptide plus its counterions adds only ~2–20 mOsm/kg, nowhere near enough to change that. The bigger story for a reagent supplier is three other things:
- Low ionic strength. The Debye length is several nanometres in a reconstituted vial versus ~0.8 nm in a 150 mM salt background. This changes how strongly peptide molecules repel each other, and therefore aggregation behavior [7,8].
- Acidity from TFA counterions [9,10].
- Benzyl alcohol is not inert: it is a documented aggregation promoter for proteins [3–5].
Debye–Hückel theory, even the extended form, is formally wrong for a 39-residue peptide carrying several charges at physiological ionic strength. The peptide is not a point charge, its size is comparable to the screening length, and its charge state shifts with the environment (charge regulation). Manning counterion condensation mostly does not apply to ordinary peptides, because their like-charge spacing is too large. The right tools are Poisson–Boltzmann or explicit models, plus measurement.
Correcting the course framing
The CHEM301 notes said reconstitution in BAC water "requires understanding colligative properties and osmotic pressure to ensure the resulting solution is isotonic." A research idea there was to "calculate the exact osmotic pressure of current BAC water formulations mixed with BPC-157 to ensure perfect isotonicity." Two corrections:
- The arithmetic settles it immediately. BW cannot become isotonic from the peptide alone at any realistic concentration (worked calculation below). The product label itself states BW is not to be used intravenously "unless the osmolar concentration of additives results in an approximate isotonic admixture," and warns that IV administration "without a solute may result in hemolysis" [1]. That is a label fact, quoted here only to establish that BW's hypotonicity is officially recognized. It is not use guidance.
- For a research-reagent supplier, osmolality is a characterization parameter, not a target to optimize. Osmolality matters to researchers designing cell or tissue experiments, where a hypotonic vehicle confounds results. PP's job is to document what the reconstituted solution actually is: osmolality, pH, counterion content, ionic strength.
The CHEM301 notes also flagged that "the Debye-Hückel limiting law assumes infinite dilution and fails at physiological ionic strengths (~0.15 M)." That's correct, but understated. For a multiply charged peptide, the theory fails long before 0.15 M.
Part 1 — Osmolality, worked
Osmolality (osmoles per kg solvent) is what freezing-point and vapor-pressure osmometers measure. USP ⟨785⟩ defines the measurement and the distinction from osmolarity (per litre of solution) [2].
Benzyl alcohol
- BW (USP): 0.9% w/v benzyl alcohol (some products use 1.1%), pH 5.7 (4.5–7.0) per the Hospira label [1].
- 9 g/L ÷ 108.14 g/mol = 83.2 mmol/L. Benzyl alcohol is a non-electrolyte (i = 1). For dilute solutions, osmolality ≈ 83 mOsm/kg if the osmotic coefficient is near 1.
- For 1.1%: about 102 mOsm/kg.
My inference: benzyl alcohol is somewhat hydrophobic and self-associates weakly, so the real osmotic coefficient may sit slightly below 1. Measure it rather than assume.
The peptide and its counterions
Take retatrutide as an example: MW 4731 g/mol (KEGG [11]). Peptides purified by RP-HPLC are typically isolated as trifluoroacetate salts [9]. Assume 3 TFA⁻ per molecule (one per protonated basic site; the true number depends on sequence and must be measured).
| Peptide conc. | Peptide (mM) | + 3 counterions | Total mOsm/kg (ideal) |
|---|---|---|---|
| 2 mg/mL | 0.42 | 1.27 | 1.7 |
| 5 mg/mL | 1.06 | 3.17 | 4.2 |
| 10 mg/mL | 2.11 | 6.34 | 8.5 |
| 20 mg/mL | 4.23 | 12.7 | 16.9 |
So BW + 5 mg/mL peptide ≈ 83 + 4 ≈ 87 mOsm/kg, about 30% of isotonic. Three refinements, all my reasoning:
- Non-ideality pushes the peptide term down. Counterions partly associate with the polyion, so the effective number of free osmotic particles per molecule is less than 1 + n. This is exactly what Manning's limiting laws quantify for true polyelectrolytes (osmotic coefficient below 1) [6]. For peptides the effect is smaller (see Part 4).
- Self-association pushes it down further. Lipidated incretins (semaglutide, liraglutide) form oligomers and micelle-like assemblies in solution [7,12]. Ten monomers in one micelle contribute one osmotic particle, not ten.
- Excess free acid pushes it up slightly. Free TFA left from incomplete drying adds osmoles and lowers pH.
Bottom line: the peptide contribution to osmolality is single-digit to low-double-digit mOsm/kg. Any vehicle's tonicity is set by its excipients, not by the peptide.
What 0.9% NaCl would look like by comparison
0.9% NaCl = 154 mM, i = 2, ideal 308 mOsm/L. With an osmotic coefficient of ~0.93 (a standard literature value, not from my references), the measured value is about 286 mOsm/kg. This is why saline is the isotonic reference. It also shows how far an ideal calculation can drift from a measured value (about 7%) even for a simple 1:1 salt.
Part 2 — pH and the TFA problem
Where TFA comes from
Reversed-phase HPLC purification uses 0.05–0.1% trifluoroacetic acid as an ion-pairing agent. Lyophilization leaves the peptide as a TFA salt [9]. TFA (pKa ≈ 0.2–0.5, a commonly cited value) is a much stronger acid than acetic acid (pKa 4.76).
Worked number (my calculation): with 3 TFA⁻ per 4731 Da peptide, TFA (114.02 g/mol as the anion) is ~6.7% of the salt's mass. A "10 mg" vial of peptide-TFA salt contains only about 9.3 mg of peptide free base. With the higher TFA loadings that arise when residual free acid is present, the gap widens. Peptide content (by amino-acid analysis, quantitative NMR or nitrogen) is a different number from HPLC purity, and CoAs routinely conflate them.
The pH of the reconstituted solution
Counterion TFA⁻ itself does not acidify: it is the conjugate base of a strong acid, balanced by protonated amines. The pH of a dissolved peptide-TFA salt is set by:
- The peptide's own acid/base groups. A peptide with many Asp/Glu and few basic residues will run acidic once the amines' protons are accounted for.
- Excess (non-stoichiometric) free TFA. Each 0.1 mM free TFA in an unbuffered solution gives pH ≈ 4.0; 0.5 mM gives pH ≈ 3.3 (my calculations, assuming full dissociation).
- Benzyl alcohol and water add essentially no buffering, and BW's own label pH can range from 4.5 to 7.0 [1].
So reconstituted peptide solutions in unbuffered BW often end up at pH 3–5. That is my expectation from the chemistry; I don't have a published survey to cite, and it should be measured in-house per product. pH matters a great deal for physical stability:
- Zapadka et al. found a pH-induced switch in GLP-1 aggregation kinetics between pH 7.5 and 8.2. At 8.2 they saw classic nucleation-polymerization. At 7.5 the lag time increased with peptide concentration, which they attributed to off-pathway species and protonation of the N-terminus [13].
- Castelletto et al. showed semaglutide forms β-sheet fibrils at pH 2.4, in contrast to the oligomers and micelles formed at higher pH [12]. An over-acidified semaglutide reagent solution is therefore not just "slightly off." It is in a different physical-state regime.
- Exenatide was relatively stable at pH 4.5 but oxidized at pH 5.5–6.5 and deamidated and aggregated at pH 7.5–8.5 [14].
TFA in biological assays
Cornish et al. found that TFA at 10⁻⁸ to 10⁻⁷ M reduced osteoblast and chondrocyte proliferation. TFA salts of amylin and calcitonin gave consistently less proliferation than HCl salts. They recommended converting peptides to the HCl or another biologically equivalent salt before biological assessment [9]. For counterion exchange, Andrushchenko et al. found that lyophilizing from 2–10 mM HCl removes essentially all TFA without altering secondary structure. Higher HCl concentrations (>10 mM unbuffered) could modify structure and reduce thermal stability [10]. This is directly actionable for a supplier offering research reagents for cell assays.
Part 3 — Ionic strength, screening and aggregation
The Debye length in a vial vs a physiological salt background
The Debye screening length in water at 25 °C is κ⁻¹ ≈ 0.304 nm / √I (I in mol/L). My computed values:
| Condition | Ionic strength I | κ⁻¹ |
|---|---|---|
| 0.35 mM peptide (z = +2) + counterions, unbuffered | ~1 mM | 9.4 nm |
| 1 mM peptide (z = +3) + 3 TFA⁻ | 6 mM | 3.9 nm |
| 10 mM buffer | ~10 mM | 3.0 nm |
| 150 mM NaCl (physiological-like) | 150 mM | 0.78 nm |
For comparison, a 4–5 kDa peptide has a hydrodynamic radius of roughly 1–1.5 nm (my estimate from typical protein size scaling). In a reconstituted vial the screening length is larger than the peptide: like-charged molecules repel each other over several diameters. In a 150 mM salt background the repulsion is screened within less than one molecular radius.
Why that matters for aggregation
- Low ionic strength often stabilizes like-charged peptides colloidally. Jarand et al. (2026) mapped liraglutide and semaglutide stability against NaCl. Increasing ionic strength "screens the Coulomb repulsion between micelles, reducing the electrostatic stabilization barrier and allowing orientation-dependent multipole attractions to promote aggregation." The aggregation was semi-irreversible. They also found that Gdn⁺ binds acidic residues and dramatically destabilizes these analogs, while Na⁺ "merely screen[s] electrostatically" [7].
- But salt effects are not just Debye screening. For amylin (IAPP, a basic 37-residue peptide of the same size class as the incretins), fibrillation rates varied >10-fold over 20–600 mM NaCl at pH 8.0. "The effect is not entirely due to Debye screening": at low ionic strength the rate depended on anion identity (electroselectivity, implicating anion binding), and at high ionic strength it followed the Hofmeister series [8].
- Counterion identity therefore matters. TFA⁻, acetate and chloride are different anions with different binding and Hofmeister behavior. My inference from [8] is that switching counterion could change fibrillation kinetics at constant pH. For PP, that's a testable hypothesis, not a claim.
- Process history matters too. Bothe et al. found that liraglutide's oligomer state is preserved through lyophilization as a "memory effect" from synthesis and purification, and that oligomer state affected aggregation propensity, fibril formation and potency [15]. Two lots with identical HPLC purity can behave differently on reconstitution.
The plasma question, answered at the right level
The CHEM301 question asked "how dramatically" plasma's ionic atmosphere alters a charged peptide's activity versus sterile water. On paper the activity effect is large. The Davies equation (an extended Debye–Hückel form) gives these values for an ion of charge z:
| I | γ (z = 1) | γ (z = 3) |
|---|---|---|
| 6 mM (vial) | 0.92 | 0.48 |
| 150 mM | 0.76 | 0.085 |
On paper, then, a z = 3 species' activity coefficient drops roughly 6-fold from vial to physiological ionic strength. Its chemical potential term RT ln γ shifts by about RT ln(0.085/0.48) ≈ −4.3 kJ/mol (my calculation).
These numbers should not be trusted quantitatively. The Davies form is empirical and validated for small ions up to roughly 0.1–0.5 M. It treats the peptide as a point charge. For a multi-charged polyion of ~1.5 nm radius in a medium with a 0.8 nm Debye length, the assumptions fail (Part 4).
My judgment is that, in plasma-like media, other factors matter far more for a lipidated incretin than the activity coefficient: binding to serum albumin, which is what semaglutide's fatty-diacid side chain was designed for [16], plus binding to divalent ions, other proteins and surfaces. Ionic atmosphere is the first-order correction for an unmodified charged peptide. For an acylated one it is a second-order correction.
Part 4 — How Debye–Hückel scales (and fails) for a 39-residue peptide
WHICH ELECTROSTATIC MODEL APPLIES TO A CHARGED PEPTIDE IN SOLUTION?
┌──────────────────────────────┐
│ IONIC STRENGTH I < ~1 mM AND │──YES──→ DH LIMITING LAW (POINT CHARGE) ≈ OK
│ NET CHARGE |z| ≤ 2 ? │
└──────────────┬───────────────┘
│NO
┌──────────────┴───────────────┐
│ κ·a < 1 ? (DEBYE LENGTH > │──YES──→ EXTENDED DH WITH FINITE SIZE a
│ PEPTIDE RADIUS a) │ (VIAL CONDITIONS, I ≈ 1–10 mM)
└──────────────┬───────────────┘
│NO (I ≈ 150 mM: κ⁻¹ 0.78 nm < a ≈ 1–1.5 nm)
┌──────────────┴───────────────┐
│ LIKE-CHARGE SPACING b < │──YES──→ MANNING CONDENSATION (ξ = lB/b > 1)
│ BJERRUM LENGTH lB = 0.71 nm? │ (POLY-LYS/ARG STRETCHES, DNA)
└──────────────┬───────────────┘
│NO (TYPICAL MIXED-CHARGE PEPTIDE)
┌──────────────┴───────────────┐
│ POISSON–BOLTZMANN / CHARGE │
│ REGULATION / EXPLICIT MD │
│ + MEASURE (ζ, DLS, OSMOMETRY)│
└──────────────────────────────┘
Why the point-charge picture breaks
- Finite size. Extended Debye–Hückel adds an ion-size parameter a: log γ = −A z²√I / (1 + B a √I). For a peptide, a is comparable to or larger than κ⁻¹ at physiological I. The correction term then dominates, and the result is sensitive to a parameter you can't define for a flexible, non-spherical chain.
- Charge distribution, not net charge. A 39-mer with, say, +5 and −6 charged groups has net charge −1 but large local charge patches and a dipole. Jarand et al. found that GLP-1 analog aggregation is governed by "multipole, orientation-dependent electrostatics … not captured by mean-field, spherically symmetric approaches" [7]. Debye–Hückel sees only z² of the net charge, which is the wrong quantity.
- Charge regulation. pKa values of ionizable groups shift with local electrostatic potential and ionic strength, so z itself changes with I. The course question's phrase "local ionic strength differs drastically from bulk" is a real effect, but it is better framed as local electrostatic potential shifting protonation equilibria (pKa shifts) than as a "local I."
- Specific ion binding. Anion binding (electroselectivity) and Hofmeister effects are outside DH entirely [8].
Manning condensation: does it apply?
Manning's theory says counterions "condense" on a linear polyion until its charge density is reduced below a critical value. The criterion is the charge parameter ξ = l_B/b > 1, where l_B ≈ 0.71 nm is the Bjerrum length in water and b is the axial spacing between like charges. The uncondensed ions are then treated in the Debye–Hückel approximation [6].
My calculations for peptides:
- Extended chain, like charge on every residue (b ≈ 0.35 nm): ξ ≈ 2.0, so condensation is expected. Only homopolymer-like stretches (poly-Lys, poly-Arg, poly-Glu) look like this.
- Like charge every 3rd residue, extended (b ≈ 1.05 nm): ξ ≈ 0.68, no condensation.
- α-helix (0.15 nm rise/residue), like charge every 3–4 residues: b ≈ 0.45–0.6 nm, ξ ≈ 1.2–1.6. Marginal, but charges in a helix spiral around the axis and are mixed in sign, so the effective like-charge density is lower.
Conclusion (my inference): Manning condensation is a minor correction for typical therapeutic-class peptides. It may matter locally for lysine-rich segments, such as the KKTETQEK region in thymosin β4 (UniProt P62328) and similar basic patches. "Polyelectrolyte" is the right word for DNA, heparin and polylysine. For a 39-mer incretin with mixed charges it is a stretch. The course called a 39-amino-acid peptide a "massive polyelectrolyte"; it is neither massive nor, mostly, a polyelectrolyte in Manning's sense.
Part 5 — Benzyl alcohol is not an inert vehicle
This was the most practically important literature finding.
- rhIL-1ra: Zhang et al. showed benzyl alcohol accelerates aggregation by binding weakly and hydrophobically to the protein. This favors "an increase in the level of partially unfolded, aggregation-competent species" without changing the global free energy of unfolding. Sucrose partially counteracted the effect [3].
- Reconstituted lyophilizates: Roy et al. found that reconstitution with 0.9% benzyl alcohol caused more aggregation than reconstitution with water. The extent tracked how much structure had been perturbed during lyophilization. High protein concentration and sucrose minimized the perturbation; NaCl in the cake was destabilizing [4].
- rhIFN-γ: Lam et al. found 0.9% benzyl alcohol induced near-UV CD changes (tertiary structure) with no far-UV change, accompanied by aggregate formation by DLS. Loss was faster at lower protein concentration and with more buffer or benzyl alcohol [5].
Transferring this to small peptides is my inference. Peptides of 5–40 residues have little tertiary structure to perturb, so the specific "partially unfolded intermediate" mechanism may not apply. On the other hand, amphipathic and lipidated peptides have hydrophobic surfaces that benzyl alcohol could interact with, and could alter oligomer and micelle equilibria. I found no peer-reviewed study of benzyl alcohol effects on GLP-1-class peptides specifically. That gap is worth filling in-house before any claim is made either way.
Part 6 — Adsorption losses at low concentration
At low concentrations, container surfaces can remove a meaningful fraction of the peptide. Goebel-Stengel et al. tested eight ¹²⁵I-labelled endocrine peptides, GLP-1 among them, in glass and plastic tubes over 48 h. They found "important differences" in binding to different surfaces. Siliconization reduced recovery, and adding 1% BSA improved it. They recommend choosing containers empirically per peptide [17].
Worked number (my estimate): protein monolayers typically hold on the order of 1–3 mg/m², a general literature range. A 2 mL vial has roughly 10 cm² of wetted inner surface, so a monolayer holds about 2 µg. In a 5 mg vial that is 0.04%, negligible. For a 10 µg/mL working dilution in 1 mL (10 µg total), it is up to 20%. Adsorption is a dilution problem: it doesn't matter for the stock vial and it matters a lot for assay preparations.
RECONSTITUTED VIAL: WHAT CONTROLS EACH PROPERTY
┌─────────────────┐ ┌───────────────────┐ ┌────────────────────────┐
│ BENZYL ALCOHOL │──→│ OSMOLALITY ~83 │ │ PEPTIDE + COUNTERIONS │
│ 0.9% (83 mM) │ │ mOsm/kg (HYPO) │←──│ +2 TO +17 mOsm/kg │
└───────┬─────────┘ └───────────────────┘ └───────────┬────────────┘
│ HYDROPHOBIC BINDING │ TFA / FREE ACID
↓ ↓
┌─────────────────┐ ┌───────────────────┐ ┌────────────────────────┐
│ AGGREGATION- │←──│ LOW IONIC STRENGTH│ │ pH (OFTEN ACIDIC, │
│ COMPETENT STATES│ │ κ⁻¹ ≈ 3–9 nm │ │ UNBUFFERED) │
└───────┬─────────┘ │ STRONG REPULSION │ └───────────┬────────────┘
│ └───────────────────┘ │
↓ ↓
┌─────────────────────────────────────────────────────────────────────┐
│ PHYSICAL STATE: MONOMER ⇌ OLIGOMER/MICELLE ⇌ FIBRIL ; + SURFACE LOSS │
└─────────────────────────────────────────────────────────────────────┘
What this means for Peptide Partners
- CoA content: report peptide content (net peptide, by AAA, qNMR or N-analysis) separately from HPLC purity, and state the counterion identity and amount (TFA %, by ion chromatography or ¹⁹F NMR). A "10 mg" vial that is 85% peptide is a material difference for researchers.
- Offer counterion options. Provide acetate or HCl salts for cell-assay customers, given TFA's documented assay interference [9]. Use HCl-exchange conditions that don't damage structure (2–10 mM HCl) [10].
- Characterize, don't claim. Never market BW-reconstituted solutions as "isotonic" or "physiological." The numbers don't support it, and it edges toward use claims. Document measured osmolality and pH of a standard reconstitution as reagent characterization.
- Benzyl alcohol compatibility testing. For lipidated incretins and amphipathic peptides, compare reconstitution in sterile water vs BW at 0, 24 h, 7 d, and 28 d at 2–8 °C. Read out by SEC, DLS and ThT, as reagent-stability data. Do not assume BW is neutral [3–5].
- pH control for fibril-prone peptides. Semaglutide forms β-sheet fibrils at low pH [12], and GLP-1 shows pH-switching aggregation kinetics [13]. Measure the pH of a standard reconstitution for each incretin SKU, and consider whether excess TFA is pushing it into a fibril-prone window.
- Adsorption guidance for researchers making dilute working solutions: low-binding plastics, a carrier protein where the assay allows, and empirical recovery checks [17]. This is lab-practice guidance for in vitro work.
- Lot-to-lot physical-state screening. Given oligomer "memory" from purification [15], add a DLS or SEC check on reconstituted incoming lots of lipidated peptides. Identical HPLC purity does not mean identical behavior.
Questions to bring to the lab
- Can we measure osmolality (freezing-point osmometer) and pH for a standard reconstitution of each top SKU, and how far do these drift between lots?
- What are the actual TFA contents of our incoming lots (IC or ¹⁹F NMR), and how much non-stoichiometric free acid do they carry?
- Do our incretin analogs show measurable aggregation differences between water and 0.9% benzyl alcohol over 28 days at 2–8 °C? Which readout is most sensitive at our concentrations?
- For semaglutide, at what pH does the reconstituted solution sit, and is it anywhere near the low-pH fibril regime [12]?
- Should we offer acetate salts as a standard option, and what does an HCl/acetate exchange cost us in yield and purity?
- Is zeta potential or DLS-based second virial coefficient (B₂₂) measurement feasible in-house as a direct measure of the colloidal stability that Debye–Hückel can't predict?
- What recovery do we see for a 1 µg/mL dilution of a hydrophobic peptide in glass vs polypropylene vs low-bind tubes after 24 h?
What I still don't know
- Measured osmotic coefficients for benzyl alcohol at 0.9%, and for lipidated peptides at mg/mL, are not something I verified. My osmolality values are ideal-solution estimates.
- I found no peer-reviewed study on benzyl alcohol-induced aggregation specific to GLP-1/GIP/glucagon-class peptides. The evidence [3–5] is from proteins.
- Whether TFA vs acetate vs chloride measurably changes fibrillation kinetics for incretins specifically is unknown to me. The amylin anion-selectivity data [8] suggest it could.
- Real pH values of reconstituted research-grade incretins in BW are not documented in literature I found. My 3–5 range is a chemistry-based expectation.
- The quantitative breakdown of Debye–Hückel for specific peptides would need Poisson–Boltzmann calculations on actual structures and ensembles, which I haven't done.
References
- Hospira, Inc. Bacteriostatic Water for Injection, USP — prescribing information (SPL). DailyMed, U.S. National Library of Medicine. setid 87d6e9dc-fe3b-4593-ac9a-d7493d1959c7. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=87d6e9dc-fe3b-4593-ac9a-d7493d1959c7
- U.S. Pharmacopeial Convention. ⟨785⟩ Osmolality and Osmolarity. USP–NF. doi:10.31003/uspnf_m99580_04_01
- Zhang Y, Roy S, Jones LS, Krishnan S, Kerwin BA, Chang BS, Manning MC, Randolph TW, Carpenter JF. Mechanism for benzyl alcohol‐induced aggregation of recombinant human interleukin‐1 receptor antagonist in aqueous solution. Journal of Pharmaceutical Sciences. 2004;93(12):3076-3089. doi:10.1002/jps.20219
- Roy S, Jung R, Kerwin BA, Randolph TW, Carpenter JF. Effects of Benzyl Alcohol on Aggregation of Recombinant Human Interleukin-1-Receptor Antagonist in Reconstituted Lyophilized Formulations. Journal of Pharmaceutical Sciences. 2005;94(2):382-396. doi:10.1002/jps.20258
- Lam XM, Patapoff TW, Nguyen TH. The Effect of Benzyl Alcohol on Recombinant Human Interferon-γ. Pharmaceutical Research. 1997;14(6):725-729. doi:10.1023/a:1012190120061
- Manning GS. Limiting Laws and Counterion Condensation in Polyelectrolyte Solutions I. Colligative Properties. The Journal of Chemical Physics. 1969;51(3):924-933. doi:10.1063/1.1672157
- Jarand CW, Zemskov I, Müller D, Stadelmaier A, Melzig L, Schönleber R, Reed WF. Anisotropic Electrostatics in the Instability of GLP-1 Analog Micelles: Effects of Electrolytes, Denaturants, pH, and Temperature. ACS Omega. 2026;11(33):49381-49401. doi:10.1021/acsomega.6c02639
- Marek PJ, Patsalo V, Green DF, Raleigh DP. Ionic Strength Effects on Amyloid Formation by Amylin Are a Complicated Interplay among Debye Screening, Ion Selectivity, and Hofmeister Effects. Biochemistry. 2012;51(43):8478-8490. doi:10.1021/bi300574r
- Cornish J, Callon KE, Lin CQX, Xiao CL, Mulvey TB, Cooper GJS, Reid IR. Trifluoroacetate, a contaminant in purified proteins, inhibits proliferation of osteoblasts and chondrocytes. American Journal of Physiology-Endocrinology and Metabolism. 1999;277(5):E779-E783. doi:10.1152/ajpendo.1999.277.5.E779
- Andrushchenko VV, Vogel HJ, Prenner EJ. Optimization of the hydrochloric acid concentration used for trifluoroacetate removal from synthetic peptides. Journal of Peptide Science. 2007;13(1):37-43. doi:10.1002/psc.793
- KEGG DRUG database. D12430 Retatrutide (USAN). Kanehisa Laboratories. https://www.kegg.jp/entry/D12430
- Castelletto V, de Mello LR, Seitsonen J, Hamley IW. Fibrillar and Micellar Aggregation of Semaglutide and Formation of a Chiral-Imprinted Glass. Biomacromolecules. 2026;27(4):2818-2827. doi:10.1021/acs.biomac.5c02669
- Zapadka KL, Becher FJ, Uddin S, Varley PG, Bishop S, Gomes dos Santos AL, Jackson SE. A pH-Induced Switch in Human Glucagon-like Peptide-1 Aggregation Kinetics. Journal of the American Chemical Society. 2016;138(50):16259-16265. doi:10.1021/jacs.6b05025
- Benet A, Halseth T, Kang J, Kim A, Ackermann R, Srinivasan S, Schwendeman S, Schwendeman A. The Effects of pH and Excipients on Exenatide Stability in Solution. Pharmaceutics. 2021;13(8):1263. doi:10.3390/pharmaceutics13081263
- Bothe JR, Andrews A, Smith KJ, Joyce LA, Krishnamachari Y, Kashi S. Peptide Oligomerization Memory Effects and Their Impact on the Physical Stability of the GLP-1 Agonist Liraglutide. Molecular Pharmaceutics. 2019;16(5):2153-2161. doi:10.1021/acs.molpharmaceut.9b00106
- Lau J, Bloch P, Schäffer L, Pettersson I, Spetzler J, Kofoed J, Madsen K, Knudsen LB, McGuire J, Steensgaard DB, Strauss HM, Gram DX, Knudsen SM, Nielsen FS, Thygesen P, Reedtz-Runge S, Kruse T. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015;58(18):7370-7380. doi:10.1021/acs.jmedchem.5b00726
- Goebel-Stengel M, Stengel A, Taché Y, Reeve JR. The importance of using the optimal plasticware and glassware in studies involving peptides. Analytical Biochemistry. 2011;414(1):38-46. doi:10.1016/j.ab.2011.02.009